Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-22T16:48:40.607Z Has data issue: false hasContentIssue false
  • English
  • Français

The Role of Negative Methicillin-Resistant Staphylococcus aureus Nasal Surveillance Swabs in Predicting the Need for Empiric Vancomycin Therapy in Intensive Care Unit Patients

Published online by Cambridge University Press:  28 January 2018

Darunee Chotiprasitsakul ,
Pranita D. Tamma ,
Avinash Gadala  and
Sara E. Cosgrove
Darunee Chotiprasitsakul*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Pranita D. Tamma
Affiliation:
Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
Avinash Gadala
Affiliation:
Department of Hospital Epidemiology and Infection Control, The Johns Hopkins Hospital, Baltimore, Maryland
Sara E. Cosgrove
Affiliation:
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
*
Address correspondence to Darunee Chotiprasitsakul, MD, MPH, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, 270 Rama 6 Road, Ratchathewi, Bangkok, Thailand 10400 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVES

The role of methicillin-resistant Staphylococcus aureus (MRSA) nasal surveillance swabs (nasal swabs) in guiding decisions about prescribing vancomycin is unclear. We aimed to determine the likelihood that patients with negative MRSA nasal swabs develop subsequent MRSA infections; to assess avoidable vancomycin days for patients with negative nasal swabs; and to identify risk factors for having a negative nasal swab and developing a MRSA infection during the intensive care unit (ICU) stay.

METHODS

This retrospective cohort study was conducted in 6 ICUs at a tertiary-care hospital from December 2013 through June 2015. The negative predictive value (NPV), defined as the ability of a negative nasal swab to predict no subsequent MRSA infection, was calculated. Days of vancomycin continued or restarted after 3 days from the collection time of the first negative nasal swab were determined. A matched case-control study identified risk factors for having a negative nasal swab and developing MRSA infection.

RESULTS

Of 11,441 patients with MRSA-negative nasal swabs, the rate of subsequent MRSA infection was 0.22%. A negative nasal swab had a NPV of 99.4% (95% confidence interval [CI], 99.1%–99.6%). Vancomycin was continued or started after nasal swab results were available in 1,431 patients, translating to 7,364 vancomycin days. No risk factors associated with MRSA infection were identified.

CONCLUSIONS

In our hospital with a low prevalence of MRSA transmission, a negative MRSA nasal swab was helpful in identifying patients with low risk of MRSA infection in whom empiric vancomycin therapy could be stopped and in whom the subsequent initiation of vancomycin therapy during an ICU admission could be avoided.

Infect Control Hosp Epidemiol 2018;39:290–296

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 3 , March 2018 , pp. 290 - 296
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. Part of this study was presented as an oral presentation at IDWeek 2017 in San Diego, California, on October 6, 2017.

References

REFERENCES

1. Liu, C, Bayer, A, Cosgrove, SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285–292.Google Scholar
2. Solomkin, JS, Mazuski, JE, Bradley, JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133–164.Google Scholar
3. Stevens, DL, Bisno, AL, Chambers, HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:e10–e52.Google Scholar
4. Kalil, AC, Metersky, ML, Klompas, M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61–e111.CrossRefGoogle Scholar
5. Jinno, S, Chang, S, Donskey, CJ. A negative nares screen in combination with absence of clinical risk factors can be used to identify patients with very low likelihood of methicillin-resistant Staphylococcus aureus infection in a Veterans Affairs hospital. Am J Infect Control 2012;40:782–786.CrossRefGoogle Scholar
6. Harris, AD, Furuno, JP, Roghmann, MC, et al. Targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy. Antimicrob Agents Chemother 2010;54:3143–3148.Google Scholar
7. Boyce, JM, Pop, OF, Abreu-Lanfranco, O, et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 2013;57:1163–1168.Google Scholar
8. Dangerfield, B, Chung, A, Webb, B, Seville, MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014;58:859–864.Google Scholar
9. Milstone, AM, Carroll, KC, Ross, T, Shangraw, KA, Perl, TM. Community-associated methicillin-resistant Staphylococcus aureus strains in pediatric intensive care unit. Emerg Infect Dis 2010;16:647–655.CrossRefGoogle ScholarPubMed
10. Pirracchio, R, Mateo, J, Raskine, L, et al. Can bacteriological upper airway samples obtained at intensive care unit admission guide empiric antibiotherapy for ventilator-associated pneumonia? Crit Care Med 2009;37:2559–2563.Google Scholar
11. Chan, JD, Dellit, TH, Choudhuri, JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. Crit Care Med 2012;40:1437–1442.Google Scholar
12. Sarikonda, KV, Micek, ST, Doherty, JA, Reichley, RM, Warren, D, Kollef, MH. Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Crit Care Med 2010;38:1991–1995.Google Scholar
13. Junior, MS, Correa, L, Marra, AR, Camargo, LF, Pereira, CA. Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study. BMC Infect Dis 2007;7:88.CrossRefGoogle Scholar
14. Carmeli, Y, Samore, MH, Huskins, C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant Enterococci: a meta-analysis. Arch Intern Med 1999;159:2461–2468.Google Scholar
15. Lodise, TP, Graves, J, Evans, A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315–3320.Google Scholar
16. Lodise, TP, Miller, CD, Graves, J, et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;62:1138–1141.Google Scholar
17. Tenover, FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008;46:675–677.Google Scholar
18. Tiwari, HK, Sen, MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from the northern part of India. BMC Infect Dis 2006;6:156.Google Scholar
19. van Hal, SJ, Paterson, DL, Lodise, TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57:734–744.Google Scholar
20. Nahimana, I, Francioli, P, Blanc, DS. Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus aureus . Clin Microbiol Infect 2006;12:1168–1174.Google Scholar
21. van Loo, IH, van Dijk, S, Verbakel-Schelle, I, Buiting, AG. Evaluation of a chromogenic agar (MRSASelect) for the detection of meticillin-resistant Staphylococcus aureus with clinical samples in The Netherlands. J Med Microbiol 2007;56:491–494.CrossRefGoogle ScholarPubMed
22. Fagan, EJ, Jenkins, C, Walton, C, James, VL. Screening methods for meticillin-resistant Staphylococcus aureus . J Med Microbiol 2010;59:1153–1155.Google Scholar
23. Marlowe, EM, Bankowski, MJ. Conventional and molecular methods for the detection of methicillin-resistant Staphylococcus aureus . J Clin Microbiol 2011;49:S52–S56.Google Scholar
24. Baker, SE, Brecher, SM, Robillard, E, Strymish, J, Lawler, E, Gupta, K. Extranasal methicillin-resistant Staphylococcus aureus colonization at admission to an acute care Veterans Affairs hospital. Infect Control Hosp Epidemiol 2010;31:42–46.Google Scholar
25. Chen, W, Li, S, Li, L, Wu, X, Zhang, W. Effects of daily bathing with chlorhexidine and acquired infection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: a meta-analysis. J Thorac Dis 2013;5:518–524.Google Scholar
26. Polk, RE, Hohmann, SF, Medvedev, S, Ibrahim, O. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis 2011;53:1100–1110.CrossRefGoogle ScholarPubMed
27. Wu, PJ, Jeyaratnam, D, Tosas, O, Cooper, BS, French, GL. Point-of-care universal screening for meticillin-resistant Staphylococcus aureus: a cluster-randomized cross-over trial. J Hosp Infect 2017;95:245–252.Google Scholar
28. Furuno, JP, Hebden, JN, Standiford, HC, et al. Prevalence of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii in a long-term acute care facility. Am J Infect Control 2008;36:468–471.Google Scholar